Up 70% since IPO Up 70% since its late March IPO, FendX Technologies (FNDX.c) is on a clear path to commercialization having recently announced the engagement of Dunmore for the scale-up development of RepelWrap.
RepelWrap is a first-of-its-kind coating product with patent-pending and proprietary technology with unique repelling properties that prevent the adhesion of pathogens, bacteria and viruses, reducing their transmission on surfaces prone to contamination.
FNDX's engagement of Dunmore is an important milestone as it's the first step to assessing and creating an automated manufacturing process, positioning FNDX for significant revenue generation once in commercial production which is expected in 2024.
By leveraging its robust patent portfolio and nanotechnology, FNDX additionally plans to "research and develop a pipeline of other products to contribute to the global effort to reduce the spread of pathogens"
Plus, FNDX has announced a range of promo contracts totalling USD$540,000 alongside their participation in the Bloom Burton & Co Healthcare Investor Conference.
The conference, held on April 25, 2023, hosts Canada's premier publicly traded and venture-backed private companies and will be attended by FNDX President & CEO Dr. Myers.
In preventing the spread of COVID and other diseases, FNDX and its RepelWrap have a unique opportunity to take advantage of as the surface coating market is estimated to hit US$3.5 billion by 2025, growing from US$1.3 billion in 2020 at an 18% CAGR.
Recent News Releases:
Posted on behalf of FendX Technologies Inc.